ID
13118
Description
Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01133704
Link
https://clinicaltrials.gov/show/NCT01133704
Keywords
Versions (1)
- 1/17/16 1/17/16 -
Uploaded on
January 17, 2016
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Hormone-Refractory Prostate Cancer NCT01133704
Eligibility Hormone-Refractory Prostate Cancer NCT01133704
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Description
visceral metastases
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0027627
- UMLS CUI [1,2]
- C0442045
Description
radiation therapy
Data type
boolean
Alias
- UMLS CUI [1]
- C1522449
Description
study subject participation status, concurrent therapy
Data type
boolean
Alias
- UMLS CUI [1]
- C2348568
- UMLS CUI [2]
- C0009429
Similar models
Eligibility Hormone-Refractory Prostate Cancer NCT01133704
- StudyEvent: Eligibility
C0007112 (UMLS CUI [1,2])
C0279025 (UMLS CUI [1,2])
C0005953 (UMLS CUI [1,2])
C0232804 (UMLS CUI [1,3])
C0442045 (UMLS CUI [1,2])
C0009429 (UMLS CUI [2])